MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
Cells · 2023
DOI: 10.3390/cells12020229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Sebastian Staebler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany. Hauptthemen laut MEDLINE: Cartilage, Osteoarthritis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Association (DFG), IZKF Erlangen “Erlanger Anschubfinanzierung (ELAN).
Abstract (Originalsprache)
Melanoma inhibitory activity/cartilage-derived retinoicacid-sensitive protein (MIA/CD-RAP) is a protein expressed and secreted by chondrocytes and cartilaginous tissues. MIA/CD-RAP-deficient mice develop milder osteoarthritis than wildtype mice. In this study, we investigated MIA/CD-RAP downstream targets to explain this reduced disease development. As a possible mediator, we could detect matrix metalloproteinase 13 (MMP13), and the influence of MIA/CD-RAP on MMP13 regulation was analyzed in vitro using SW1353 chondrosarcoma cells and primary chondrocytes. The femoral head cartilage of WT and MIA/CD-RAP −/− mice were cultured ex vivo to further investigate MMP13 activity. Finally, osteoarthritis was surgically induced via DMM in C57BL/6 mice, and the animals were treated with an MIA/CD-RAP inhibitory peptide by subcutaneously implanted pellets. MMP13 was regulated by MIA/CD-RAP in SW1353 cells, and MIA/CD-RAP −/− murine chondrocytes showed less expression of MMP13. Further, IL-1β-treated MIA/CD-RAP −/− chondrocytes displayed less MMP13 expression and activity. Additionally, MIA/CD-RAP-deficient ex vivo cultured cartilage explants showed less MMP13 activity as well as reduced cartilage degradation. The mice treated with the MIA/CD-RAP inhibitory peptide showed less osteoarthritis development. Our findings revealed MIA/CD-RAP as a new regulator of MMP13 and highlighted its role as a potential new target for osteoarthritis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany.
- Institute of Pathology, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054 Erlangen, Germany.
- Institute of Applied Pathology, 67346 Speyer, Germany.
- Institute of Pathology, Medical School, University of Regensburg, 93053 Regensburg, Germany.
ORCID-Profile: Sebastian Staebler, Ulrike Rottensteiner-Brandl, Anja Bosserhoff
Förderung
- German Research Association (DFG)
- IZKF Erlangen “Erlanger Anschubfinanzierung (ELAN)
Zitieren
APA
Staebler, S., Lichtblau, A., Gurbiel, S., Schubert, T., Riechers, A., Rottensteiner-Brandl, U., & Bosserhoff, A. (2023). MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy. Cells. https://doi.org/10.3390/cells12020229
Vancouver
Staebler S, Lichtblau A, Gurbiel S, Schubert T, Riechers A, Rottensteiner-Brandl U, et al. MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy. Cells. 2023. doi:10.3390/cells12020229
BibTeX
@article{Staebler2023,
author = {Staebler, Sebastian and Lichtblau, Adrian and Gurbiel, Slavyana and Schubert, Thomas and Riechers, Alexander and Rottensteiner-Brandl, Ulrike and Bosserhoff, Anja},
title = {MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12020229}
}
EUVIMED